Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML)

Leuk Lymphoma. 2022 Dec;63(13):3232-3236. doi: 10.1080/10428194.2022.2116934. Epub 2022 Sep 10.

Authors

Brian J Ball¹, Shukaib Arslan¹, Paul Koller¹, Dat Ngo¹, Michelle Afkhami¹, Amandeep Salhotra¹, Monzr Al-Malki¹, Ahmed Aribi¹, Haris Ali¹, Karamjeet Sandhu¹, Salman Otoukesh¹, Idoroenyi Amanam¹, Hoda Pourhassan¹, Andrew Artz¹, Peter Curtin¹, Anthony Stein¹, Ryotaro Nakamura¹, Guido Marcucci¹, Eileen Smith¹, Vinod Pullarkat¹, Ibrahim Aldoss¹

Affiliation

¹ Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA, USA.

PMID: 36089918
DOI: 10.1080/10428194.2022.2116934

No abstract available

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Bridged Bicyclo Compounds, Heterocyclic* / therapeutic use
Humans
Leukemia, Myeloid, Acute* / diagnosis
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / genetics
Sulfonamides / therapeutic use

Substances

venetoclax
Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides

Grants and funding

K12 CA001727/CA/NCI NIH HHS/United States